New analysis of Novartis data confirms that Cosentyx demonstrates durable comprehensive treatment across psoriatic disease

For the first time efficacy and safety data from dedicated phase III trials are analyzed together in one abstract, backing Cosentyx as comprehensive treatment across multiple manifestations of psoriatic disease and ankylosing spondylitis. The abstract presented at the World Congress of Dermatology in Milan shows the long-term efficacy and safety of Cosentyx in multiple manifestations of psoriatic disease including moderate-to-severe plaque-type, nail and palmoplantar psoriasis, psoriatic arthritis and ankylosing spondylitis -   Proven efficacy of treatments in persistent manifestations of nails, scalp and palmoplantar psoriasis is a specific concern for patients as these are significantly reducing the quality of life and are impacting up to 9 out of 10 psoriasis patients , -   Additional new 5 year data with Cosentyx confirmed low immunogenicity with rates year-over-year consistently below 1% in patients with moderate to severe plaque psoriasis -   Cosentyx is reimagining patient care with a wealth of research from 100 studies and has been proven to offer clear or almost clear skin in 8 out of 10 patients within 16 weeks of treatment.